Top Israeli Scientist & Physician Embraces Ivermectin for Clinical Trial & Raises Possibility the Drug Could Beat COVID-19

Jun 15, 2020 | COVID-19, Israel, Ivermectin, Sheba Medical Center

Top Israeli Scientist & Physician Embraces Ivermectin for Clinical Trial & Raises Possibility the Drug Could Beat COVID-19

Professor Eli Schwartz, founder of the Center for Travel Medicine and Tropical Disease at Sheba Medical Center, Tel Hashomer, launched a clinical trial involving ivermectin, the broad-spectrum antiparasitic therapy that absolutely destroyed the novel coronavirus pathogen in an Australian lab experiment. Professor Schwartz undoubtedly has been scanning the use of ivermectin like TrialSite News has been reporting on it: the momentum behind the movement can’t be denied. The drug, Professor Schwartz posits, may be some form of cure.

TrialSite News recently showcased the study in Sheba Medical Center, Israel’s number one health provider and the 9th top health center worldwide. Recently, Schwartz informed The Jerusalem Post that the drug, now tested in mild to moderate cases, launched an  investigation to determine if the regimen can significantly shorten the viral shedding period, allowing patients to post negative tests for COVID-19 and hence shorten the isolation period to just a few days. Currently, the infection can last at least two weeks and Gilead’s remdesivir helped reduce this amount by a few days. What if an economical and available drug could do far better?

Principal Investigator Comment

Professor Schwartz commented, “From a public health point of view, this is very important,” noting that if there was an economical and available cure such as this for the most part those that would fall ill would get better far more quickly and be back to work hence contributing to the economy’s productivity.

The Study

To date, The Jerusalem Post reports the study has enrolled 26 participants in the randomized, controlled trial: the protocol calls for 100 participants. Most of the recruits will be at what The Jerusalem Post refers to as state-run “coronavirus hotels.”

Nobel Prize

In 2015, a team of researchers won a Nobel Prize for the discovery of Ivermectin. Millions have been treated with the dru,g which has a known safety profile that clinical investigational teams can work with.

Growing Momentum

As TrialSite News has reported, in Peru thousands of been treated with ivermectin and the drug has been given the greenlight by the regulatory authorities. In Bolivia, regional governments are giving out hundreds of thousands of doses, while in Bangladesh TrialSite News interviewed doctor Tarek Alam that reported astounding results at the Bangladesh Medical College. TrialSite News has interviewed Dr. Jean-Jaque Rajter who treated patients in Broward County Florida. The observational protocol, approved by the Broward Health Board, led to materially positive results, which were recently uploaded to the preprint server. Now at least 23 random controlled trials involving ivermectin are ongoing, including those sponsored by the University of Kentucky and Johns Hopkins University. Sanford Health is purportedly also planning an ivermectin trial in the Great Plains region of America.

Lead Research/Investigator

Professor Eli Schwartz, founder of the Center for Travel Medicine and Tropical Disease at Sheba Medical Center, Tel Hashomer

Call to Action: Follow the link to The Jerusalem Post article to learn more.


  1. Arun Kumar Laha

    COVID19 and Ivermectin
    High population density plus unlocking lead to community transmission, resulting in fast increase in the number of COVID19 cases in India. Good news is that, large number of infected persons would be cured of the disease without much symptoms; these asymptomatic persons would not subject themselves to any form of testing or treatment; they would roam freely in society and would infect more persons – and this would usher in HERD IMMUNITY in India.

    Patients with mild-to-moderate symptoms do not require costly indoor treatment; and such patients should be treated by doctors at the periphery; and the doctors should treat these patients based on clinical assessments of the patients – elaborate testing, to exclude COVID19, for each and every persons suffering from fever with mild-to-moderate Flu-like symptoms is a very costly proposition. There would be severe forms of chaos if we try to cater indoor treatment to all symptomatic patients presenting with mild-to-moderate Flu-like features. However, severely ill patients, aged patients with comorbidities should be admitted in well-equipped institutions.

    ICMR should allow doctors, not attached to any state-run hospital or private institution, to treat patients with mild-to-moderate Flu-like symptoms with a cocktail of drugs – Vitamin D, Vitamin C, Zinc, Azithromycin and Ivermectin. Doctors attached to state-run or private institutions are, I think, already instructed by ICMR about management of such patients at indoor and outdoor.

    COVID19 is a Global emergency; we do not have much time for elaborate clinical trials (multi-centric, double-blind, placebo-controlled, above all, reports should be acceptable to peer-group-reviewed international Journals) to prove or disprove efficacy of Ivermectin in treating COVID19. Doctors of many nations have published reports proving excellent efficacy of Ivermectin; no doubt, these studies have been conducted with a small number of patients; but still, we cannot discard the inferences of these reports out right, because these findings are collected by senior physicians with long experiences in clinical medicine.

    Arun Kumar Laha 09 06 2020


    Times Of India published two reports on 21st and 22th May praising Rendesivir and Favipiravir, two antivirals. Mainstream media worldwide are promoting these drugs of big pharma companies; however, most, if not all, antivirals are of questionable efficacy. No one is promoting IVERMECTIN, a cheap oral drug, prescribing which against COVID19 doctors from many nations, including Bangladesh, got EXCELLENT results. No one is interested in promoting this off patented molecule. Scientists could not fabricate vaccines against all and every pathogenic Virus; most probably, COVID19 is one of such type. Monoclonal antibody against viral proteins, however, is a good treatment plan.


    Fight against COVID19

    To fight against COVID19 India has to chalk out her own plan; we should not ape other nations. There would be serious socio-economic disaster in India if we continue total or partial lockdown. Most of the COVID19 infected patients in India are asymptomatic; and this might be due to the presence of Curcumin in our daily food. So, it is very difficult to determine patient- load in India; we can not test for COVID19 in all persons under the Sun.

    Asymptomatic persons would refuse testing and any form of treatment – they would roam freely in society; and would infect the population at large; and this will in near future usher in HERD IMMUNITY in India. Most of the symptomatic patients present with mild to moderate illness; we should treat them as OPD patients. We have to treat these patients with mild-to-moderate Flu-like symptoms as quickly as possible; so that they do not become severely ill to overwhelm the scarce indoor facilities in our country. Here is a safe outdoor treatment plan that will show quick and effective response in symptomatic patients (for adults): – Vitamin D & C and Zinc daily in usual recommended doses + Virostatic drug Ivermectin 12mg daily for 3 to 5 days + Senolytic antibiotic Azithromycin 250mg to 500mg daily for 5 days to 10 days. This treatment plan ushers in prompt response. Serious indoor patients would get these medicines + necessary supportive measures + Hydroxychloroquine (HCQS). – Arun Kumar Laha 29, Abinash Banerjee Lane. Howrah 711104. (

    Disclaimer: –

    This is not a prescription for the general public to self- medicate themselves. It is for the medical fraternity to think about my humble suggestion.

    To solve the problems of COVID 19, lockdown is not the only way out; we have to rely on development of HERD IMMUNITY by exposing people to low grade infection with COVID19 and we have to treat the symptomatic patients as fast as possible, to cut short the number of serious patients requiring indoor treatment.

    Many health- care personnel and other fighters against COVID19 are losing their lives to save humanity at large; ICMR should think about prescribing IVERMECTIN (12mg in empty stomach once in a week instead of Hydroxychloroquine) to these persons. Ivermectin is safer than Hydroxychloroquine.

  2. Walt

    I have been following Ivermectin through TrialSite since the Australian study was published. It has been encouraging to say the least. But now that Bolivia, Peru and Bangladesh are treating in large numbers are there any results? Can TrialSite interview the doctors critically involved and get their perspectives so that this cure will finally be realized worldwide? Great work TrialSite, we need you to continue this great public service and keep pushing. Unbelieveable that you are still the only reliable and consistent source of ivermectin information out there.

    • dan saviano

      I am a Chicago physician and have been prescribing IVERMECTIN 24mg po x one day and z pack, or 12mg po (4 x3mg tab ) x 3 days and z pack at positive PCR, or onset of symptoms- fever, cough,sob, sore throat etc. with history of exposure (patients, family, co worker). Most symptoms resolve 3-5 days. quaranteen for total of 14 days. Pick up your immunity card.

      • Arun Kumar Laha

        Send your observations to USFDA and ICMR.

  3. Vincent

    Wonderful work! So sad journalists don’t spread the good news but only lies and what the industry tells them to say about all this… We people are sick to read so much bullish**… Dr Didier Raoult’s work in France is also very interesting. Hopefully future will show the real faces of the ones who lied and manipulated us.

  4. John Lipovsky

    Use FDA ‘Real World Evidence” where possible to determine best Off Label treatments to establish current best treatments. Anecdotal evidence is data to be used.

Pin It on Pinterest